論文種別 原著(症例報告除く)
言語種別 英語
査読の有無 その他(不明)
表題 Reliable Performance of mALBI Grade-Based Risk Models for Predicting the Prognosis of Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab as First-Line Treatment: Comparative Analysis of 13 Risk Models
掲載誌名 正式名:Journal of gastroenterology and hepatology
略  称:J Gastroenterol Hepatol
ISSNコード:08159319/14401746
掲載区分国外
巻・号・頁 40(4),pp.930-939
著者・共著者 Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J,
Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri
K, Toyoda H, Ogawa C, Nishikawa H, Nishimura T, Kawata K, Kosaka H, Naganuma A,
Yata Y, Ohama H, Kuroda H, Matono T, Tanaka K, Tada F, Nouso K, Morishita A,
Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S,
Kaibori M, Iijima H, Hiasa Y, Kumada T; Real‐life Practice Experts for HCC
(RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48
clinics in Japan).
発行年月 2025/04
DOI 10.1111/jgh.16871
PMID 39762722